Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers

Bibliographic Details
Main Authors: Bryant, Christopher, Rawlinson, Rebecca, Massey, Andrew J
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137066/
id pubmed-4137066
recordtype oai_dc
spelling pubmed-41370662014-08-19 Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers Bryant, Christopher Rawlinson, Rebecca Massey, Andrew J Research Article BioMed Central 2014-08-07 /pmc/articles/PMC4137066/ /pubmed/25104095 http://dx.doi.org/10.1186/1471-2407-14-570 Text en © Bryant et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Bryant, Christopher
Rawlinson, Rebecca
Massey, Andrew J
spellingShingle Bryant, Christopher
Rawlinson, Rebecca
Massey, Andrew J
Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
author_facet Bryant, Christopher
Rawlinson, Rebecca
Massey, Andrew J
author_sort Bryant, Christopher
title Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
title_short Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
title_full Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
title_fullStr Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
title_full_unstemmed Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
title_sort chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
description
publisher BioMed Central
publishDate 2014
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4137066/
_version_ 1613125290465165312

Similar Items